Our lead compound, Abivertinib, a small molecule kinase inhibitor, is currently under review by the China Food and Drug Administration (CFDA) for the treatment of patients with non-small cell lung cancer (NSCLC) containing the EGFR T790M mutation. A second small molecule kinase inhibitor, AC0058, has entered Phase 1B development in the US for the treatment of systemic lupus erythematosus (SLE).
Alongside a robust R&D organization, ACEA has established drug manufacturing and commercial capabilities in China to support our long-term growth. This infrastructure provides us greater control over our supply chain to make sure products are delivered to patients on-time and at the highest quality.
We believe ACEA is well-position to deliver on its promise to bring innovative treatments to patients while creating value for shareholders, employees, and society.